Prognostic Factors in Japanese EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Real-World Single-Center Retrospective Cohort Study
The patients who were T790M-positive in the first-line treatment with first or second-generation EGFR-TKIs and were given osimertinib as the second or later line treatment had a better prognosis than the patients who were T790M-negative in the first-line treatment with first or second-generation EGFR-TKIs and could not receive osimertinib.
Authors
- Hiroki Wakabayashi (ORCID: https://orcid.org/0000-0002-8705-441X)
- Atsuhito Saiki (ORCID: https://orcid.org/0000-0003-4009-9386)
- Kenta Takashima (ORCID: https://orcid.org/0009-0009-3631-2376)
- Yasuo Matsuzawa (ORCID: https://orcid.org/0000-0001-7470-6303)
- Yu Murakami
Institutions
- Toho University (JP)
- Toho University Medical Center Sakura Hospital (JP)
Publication Details
- Journal
- Drugs - Real World Outcomes
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1007/s40801-024-00449-8
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.42